-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

Benzinga·08/13/2026 11:56:36
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.